恒瑞医药：获得9个药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for multiple clinical trial applications, indicating a significant advancement in its drug development pipeline [1] Group 1: Clinical Trial Approvals - The company and its subsidiaries have been granted clinical trial approval for several products, including HRS-4642 injection, SHR-1701 injection, SHR-7367 injection, SHR-8068 injection, Adalimumab injection, Bevacizumab injection, SHR-A2102 for injection, Apalutamide capsules, and Darsylis sulfate tablets [1] - Notably, HRS-4642 injection, SHR-1701 injection, and SHR-7367 injection have no similar products approved for market in both domestic and international markets [1]